Konstantinos E Hatzistergos
Overview
Explore the profile of Konstantinos E Hatzistergos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
2103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dulce R, Hatzistergos K, Kanashiro-Takeuchi R, Takeuchi L, Balkan W, Hare J
Rev Endocr Metab Disord
. 2025 Jan;
PMID: 39883351
Growth hormone (GH)-releasing hormone (GHRH), a hypothalamic peptide initially characterized for its role in GH regulation, has gained increasing attention due to its GH-independent action on peripheral physiology, including that...
2.
Konstantopoulos G, Leventakou D, Saltiel D, Zervoudi E, Logotheti E, Pettas S, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772274
Amanda Psyrri was not included as an author in the original publication [...].
3.
Siokatas G, Hamouche R, Maneta E, Selzman C, Hatzistergos K, Drakos S, et al.
J Am Heart Assoc
. 2024 Aug;
13(16):e035661.
PMID: 39136355
No abstract available.
4.
Konstantopoulos G, Leventakou D, Saltiel D, Zervoudi E, Logotheti E, Pettas S, et al.
Viruses
. 2024 Jan;
16(1).
PMID: 38257813
Human Papillomaviruses have been associated with the occurrence of cervical cancer, the fourth most common cancer that affects women globally, while 70% of cases are caused by infection with the...
5.
Pechlivani E, Pemas S, Kanlis A, Pechlivani P, Petrakis S, Papadimitriou A, et al.
Micromachines (Basel)
. 2023 Oct;
14(10).
PMID: 37893266
In the last decade, there has been a notable advancement in diverse bioreactor types catering to various applications. However, conventional bioreactors often exhibit bulkiness and high costs, making them less...
6.
Siokatas G, Papatheodorou I, Daiou A, Lazou A, Hatzistergos K, Kararigas G
J Cardiovasc Dev Dis
. 2022 Mar;
9(3).
PMID: 35323638
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality. Interestingly, male and female patients with CVD exhibit distinct epidemiological and pathophysiological characteristics, implying a potentially important role for...
7.
Daiou A, Petalidou K, Siokatas G, Papadopoulos E, Hatzistergos K
Int J Dev Biol
. 2021 Dec;
66(1-2-3):59-75.
PMID: 34881787
Current progress and challenges in understanding the molecular and cellular mechanisms of cardiomyocyte embryonic development and regeneration are reviewed in our present work. Three major topics are critically discussed: how...
8.
Salerno A, Wanschel A, Dulce R, Hatzistergos K, Balkan W, Hare J
J Cardiovasc Aging
. 2021 Nov;
1.
PMID: 34790975
Introduction: Induced pluripotent stem cells (iPSCs) provide a model of cardiomyocyte (CM) maturation. Nitric oxide signaling promotes CM differentiation and maturation, although the mechanisms remain controversial. Aim: The study tested...
9.
Hatzistergos K, Durante M, Valasaki K, Wanschel A, Harbour J, Hare J
Sci Adv
. 2020 Dec;
6(49).
PMID: 33268364
The degree to which populations of cardiac progenitors (CPCs) persist in the postnatal heart remains a controversial issue in cardiobiology. To address this question, we conducted a spatiotemporally resolved analysis...
10.
Yousefi K, Irion C, Takeuchi L, Ding W, Lambert G, Eisenberg T, et al.
J Am Coll Cardiol
. 2019 Jun;
73(21):2705-2718.
PMID: 31146816
Background: Patients with chronic kidney disease (CKD) and coincident heart failure with preserved ejection fraction (HFpEF) may constitute a distinct HFpEF phenotype. Osteopontin (OPN) is a biomarker of HFpEF and...